Depression in Parkinson's disease: the effectiveness and risk of pharmacotherapy. Clinical review

E-ISSN： 1479-8301|15|2|147-153

ISSN： 1346-3500

Source： Psychogeriatrics, Vol.15, Iss.2, 2015-06, pp. : 147-153

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rasagiline in the pharmacotherapy of Parkinson’s disease – a review

By Rascol Olivier

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 12, 2005-10 ,pp. : 2061-2075

Informa Healthcare

Access to resources Recommend Favorite

Parkinson's disease: emerging pharmacotherapy

By Strecker Karl Schwarz Johannes

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 4, 2008-12 ,pp. : 573-591

Informa Healthcare

Access to resources Recommend Favorite

The Role of Dopamine Agonists in the Treatment of Depression in Patients with Parkinson's Disease: A Systematic Review

By Leentjens Albert F.G.

Drugs, Vol. 71, Iss. 3, 2011-02 ,pp. : 273-286

Adis International

Access to resources Recommend Favorite

Modelling the Cost Effectiveness of Treatments for Parkinson's Disease: A Methodological Review

By Dams Judith

PharmacoEconomics, Vol. 29, Iss. 12, 2011-12 ,pp. : 1025-1049

Adis International

Access to resources Recommend Favorite

The Role of Iron in Neurodegeneration: Prospects for Pharmacotherapy of Parkinson's Disease

By Jellinger K.A.

Drugs & Aging, Vol. 14, Iss. 2, 1999-02 ,pp. : 115-140

Adis International

Access to resources Recommend Favorite